donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GBT Global Blood Therapeutics
32.280
+2.440+8.18%
Pre Mkt Price
32.28000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
71.34% 4.3K 221.28% 3.58K 221.28% 3.58K -54.94% 4.06K
Receivable Turnover(T)
-29.59% 9.1691 -31.58% 8.4125 -31.58% 8.4125 58.05% 9.4648
Inventory Turnover(T)
-14.66% 0.0727 -29.6% 0.0674 -29.6% 0.0674 130.66% 0.0732
Fixed Assets Turnover(T)
48.95% 2.4954 54.51% 2.2706 54.51% 2.2706 44.33% 2.0662
Total Asset Rate(T)
29.8% 0.2776 43.77% 0.2342 43.77% 0.2342 132.25% 0.2771
ROIC
-13.5% -42.952% -9.68% -38.847% -9.68% -38.847% -5.66% -45.802%
ROE
-121.34% -124.532% -98.84% -98.958% -98.84% -98.958% -43.39% -72.410%
ROA
-13.62% -40.750% -11.9% -36.446% -11.9% -36.446% -7.5% -42.699%
Efficiency Ratios
ROE 5 Year Average
-- -- -20.93% -56.094% -- -- -- --
ROA 5 Year Average
-- -- 5.12% -36.874% -- -- -- --
Average 5 Years ROIC
-- -- 5.56% -39.309% -- -- -- --
Profitability Ratios TTM
Gross Margin
-0.16% 98.204% -0.1% 98.297% -0.1% 98.297% -0.47% 98.265%
Operating Margin
15.62% -137.332% 25.09% -147.723% 25.09% -147.723% 57.21% -147.315%
Net Margin
12.47% -146.815% 22.17% -155.632% 22.17% -155.632% 53.71% -154.111%
EBITDA Margin
13.44% -1.329% 21.97% -1.4302% 21.97% -1.4302% 58.4% -1.4111%
R & D Expense Ratio
-9.14% 101.540% -13.06% 108.930% -13.06% 108.930% -48.99% 107.940%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
680.17% 487.426% 507.74% 332.950% 507.74% 332.950% 115.95% 72.818%
Total Assets to Common Equity
262.64% 648.903% 174.86% 478.188% 174.86% 478.188% 30.5% 197.106%
Debt to Asset Ratio
670.11% 491.822% 500.28% 335.837% 500.28% 335.837% 114.73% 74.587%
Current Ratio
-9.99% 8.5196 13.94% 9.1135 13.94% 9.1135 -13.48% 6.6011
Quick Ratio
-13.63% 7.328 10.79% 8.1083 10.79% 8.1083 -20.98% 5.5358
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
CEO: Love M.D., Ted W.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...